Ark Genomic Revolution Etf Profile
ARKG Etf | USD 25.43 0.59 2.38% |
Performance0 of 100
| Odds Of DistressLess than 9
|
ARK Genomic is trading at 25.43 as of the 28th of November 2024. This is a 2.38 percent increase since the beginning of the trading day. The etf's lowest day price was 25.06. ARK Genomic has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for ARK Genomic Revolution are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . More on ARK Genomic Revolution
Moving together with ARK Etf
0.64 | XLV | Health Care Select | PairCorr |
0.7 | VHT | Vanguard Health Care | PairCorr |
0.83 | IBB | iShares Biotechnology ETF | PairCorr |
0.83 | XBI | SPDR SP Biotech | PairCorr |
0.61 | IXJ | iShares Global Healthcare | PairCorr |
Moving against ARK Etf
ARK Etf Highlights
Thematic Ideas | (View all Themes) |
Old Name | BMO ARK Genomic Revolution Fund |
Business Concentration | Strategy ETFs, Theme ETFs, Health, ARK ETF Trust (View all Sectors) |
Issuer | ARK |
Inception Date | 2014-10-31 |
Entity Type | Regulated Investment Company |
Asset Under Management | 1.21 Billion |
Average Trading Valume | 2.75 Million |
Asset Type | Equity |
Category | Strategy |
Focus | Theme |
Market Concentration | Blended Development |
Region | Global |
Administrator | The Bank of NewYork Mellon Corporation |
Advisor | ARK Investment Management LLC |
Custodian | The Bank of NewYork Mellon Corporation |
Distributor | Foreside Fund Services, LLC |
Portfolio Manager | Catherine Wood |
Transfer Agent | The Bank of NewYork Mellon Corporation |
Fiscal Year End | 31-Jul |
Exchange | Cboe BZX Exchange, Inc. |
Number of Constituents | 38.0 |
Market Maker | Jane Street |
Total Expense | 0.75 |
Management Fee | 0.75 |
Country Name | USA |
Returns Y T D | (24.29) |
Name | ARK Genomic Revolution ETF |
Currency Code | USD |
Open Figi | BBG007FJPCB0 |
In Threey Volatility | 41.27 |
1y Volatility | 44.71 |
200 Day M A | 25.9029 |
50 Day M A | 24.6732 |
Code | ARKG |
Updated At | 27th of November 2024 |
Currency Name | US Dollar |
In Threey Sharp Ratio | (0.83) |
ARK Genomic Revolution [ARKG] is traded in USA and was established 2014-10-31. The fund is listed under Health category and is part of ARK ETF Trust family. The entity is thematically classified as Strategy ETFs. ARK Genomic Revolution presently have 2.36 B in assets under management (AUM). , while the total return for the last 3 years was -27.1%.
Check ARK Genomic Probability Of Bankruptcy
Geographic Allocation (%)
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on ARK Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding ARK Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as ARK Genomic Revolution Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top ARK Genomic Revolution Etf Constituents
BMY | Bristol Myers Squibb | Stock | Health Care | |
REGN | Regeneron Pharmaceuticals | Stock | Health Care | |
EDIT | Editas Medicine | Stock | Health Care | |
TAK | Takeda Pharmaceutical Co | Stock | Health Care | |
MCRB | Seres Therapeutics | Stock | Health Care | |
CGEN | Compugen | Stock | Health Care | |
ILMN | Illumina | Stock | Health Care | |
VCYT | Veracyte | Stock | Health Care |
ARK Genomic Top Holders
ADOCX | Alger Dynamic Opportunities | Mutual Fund | Long-Short Equity | |
SPEDX | Alger Dynamic Opportunities | Mutual Fund | Long-Short Equity | |
TMAT | Main Thematic Innovation | Etf | Global Small/Mid Stock | |
JAVAX | James Aggressive Allocation | Mutual Fund | Allocation--70% to 85% Equity | |
DALT | Regents Park Funds | Etf | Multistrategy |
ARK Genomic Revolution Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ARK Genomic. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
Mean Deviation | 1.81 | |||
Standard Deviation | 2.36 | |||
Variance | 5.56 | |||
Risk Adjusted Performance | (0.02) |
ARK Genomic Revolution Technical Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. ARK Genomic Revolution Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe ARK Genomic price patterns.
ARK Genomic Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARK Genomic Revolution. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.